EA201500373A1 - Маситиниб или его соль для лечения рака, фармацевтическая композиция, лекарственное средство и набор - Google Patents
Маситиниб или его соль для лечения рака, фармацевтическая композиция, лекарственное средство и наборInfo
- Publication number
- EA201500373A1 EA201500373A1 EA201500373A EA201500373A EA201500373A1 EA 201500373 A1 EA201500373 A1 EA 201500373A1 EA 201500373 A EA201500373 A EA 201500373A EA 201500373 A EA201500373 A EA 201500373A EA 201500373 A1 EA201500373 A1 EA 201500373A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- inhibitor
- tyrosine kinase
- mast cell
- treatment
- present
- Prior art date
Links
- 239000002139 L01XE22 - Masitinib Substances 0.000 title abstract 4
- WJEOLQLKVOPQFV-UHFFFAOYSA-N masitinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3SC=C(N=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 WJEOLQLKVOPQFV-UHFFFAOYSA-N 0.000 title abstract 4
- 229960004655 masitinib Drugs 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
- 238000000034 method Methods 0.000 abstract 5
- 229940124204 C-kit inhibitor Drugs 0.000 abstract 4
- 210000003630 histaminocyte Anatomy 0.000 abstract 4
- 239000003112 inhibitor Substances 0.000 abstract 4
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 abstract 4
- 239000005483 tyrosine kinase inhibitor Substances 0.000 abstract 4
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 abstract 4
- 239000002246 antineoplastic agent Substances 0.000 abstract 3
- 230000014509 gene expression Effects 0.000 abstract 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 239000000090 biomarker Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 239000003550 marker Substances 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
- 210000004976 peripheral blood cell Anatomy 0.000 abstract 1
- 239000000092 prognostic biomarker Substances 0.000 abstract 1
- 230000004797 therapeutic response Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Настоящее изобретение относится к способу лечения пациентов, страдающих от рака, при этом указанные пациенты получают лечение ингибитором тирозинкиназы, ингибитором тучных клеток или c-Kit ингибитором, в частности маситинибом, возможно в комбинации по крайней мере с одним противоопухолевым агентом. Ингибитор тирозинкиназы, ингибитор тучных клеток или c-Kit ингибитор и, возможно, по крайней мере один противоопухолевый агент, вводятся в режиме дозирования, который обеспечивает поступление терапевтически эффективного количества. Настоящее изобретение также относится к способам прогнозирования терапевтического ответа на указанное лечение у конкретного пациента и, следовательно, к установлению соответствующих субпопуляций пациентов на основании указанных прогностических факторов; в некоторых случаях обозначаемых как биомаркеры. Один способ основан на определении клинического маркера интенсивности боли. Второй способ основан на генной экспрессии прогностических биомаркеров, которую определяют на основании экспрессии РНК в клетках периферической крови, образцы которой получают перед началом лечения соединением, заявленным в соответствии с настоящим изобретением (т.е. ингибитором тирозинкиназы, ингибитором тучных клеток или c-Kit ингибитором, в частности маситинибом). Предпочтительно настоящее изобретение относится к способу лечения пациентов, страдающих раком поджелудочной железы, при этом указанные пациенты получают лечение ингибитором тирозинкиназы, ингибитором тучных клеток или c-Kit ингибитором, в частности маситинибом, возможно в комбинации по крайней мере с одним противоопухолевым агентом, в частности
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12306214 | 2012-10-04 | ||
| PCT/EP2013/070741 WO2014053650A1 (en) | 2012-10-04 | 2013-10-04 | Use of masitinib for treatment of cancer in patient subpopulations identified using predictor factors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201500373A1 true EA201500373A1 (ru) | 2016-02-29 |
| EA037368B1 EA037368B1 (ru) | 2021-03-19 |
Family
ID=47073382
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201500373A EA037368B1 (ru) | 2012-10-04 | 2013-10-04 | Способ лечения рака поджелудочной железы у пациента, страдающего от связанной с болезнью интенсивной боли, и применение набора, содержащего маситиниб или его фармацевтически приемлемую соль и гемцитаниб, для лечения рака поджелудочной железы |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US10238649B2 (ru) |
| EP (1) | EP2903616B8 (ru) |
| JP (1) | JP6234466B2 (ru) |
| KR (1) | KR102149483B1 (ru) |
| CN (1) | CN104968347A (ru) |
| AR (1) | AR092899A1 (ru) |
| AU (1) | AU2013326463B2 (ru) |
| BR (1) | BR112015007144A2 (ru) |
| CA (1) | CA2886979C (ru) |
| DK (1) | DK2903616T3 (ru) |
| EA (1) | EA037368B1 (ru) |
| ES (1) | ES2656640T3 (ru) |
| IL (1) | IL238107B (ru) |
| MX (1) | MX369999B (ru) |
| NZ (1) | NZ706420A (ru) |
| SG (1) | SG11201502626PA (ru) |
| SI (1) | SI2903616T1 (ru) |
| TW (1) | TWI609686B (ru) |
| WO (1) | WO2014053650A1 (ru) |
| ZA (1) | ZA201503054B (ru) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3052103A1 (en) * | 2013-10-04 | 2016-08-10 | AB Science | Method for determining the prognosis of pancreatic cancer |
| JP2017519727A (ja) * | 2014-05-08 | 2017-07-20 | オンコエシックス ゲーエムベーハー | チエノトリアゾロジアゼピン化合物を用いる三種陰性乳癌の治療方法 |
| WO2016062272A1 (zh) * | 2014-10-24 | 2016-04-28 | 朗齐生物医学股份有限公司 | 免疫疾病用药物在制备抑制癌症的医药组合物中的应用 |
| ES2863500T3 (es) | 2015-04-10 | 2021-10-11 | Capsugel Belgium Nv | Formulaciones lipídicas de acetato de abiraterona |
| SG10202007520WA (en) | 2016-03-02 | 2020-09-29 | Eisai R&D Man Co Ltd | Eribulin-based antibody-drug conjugates and methods of use |
| JP7250312B2 (ja) * | 2016-03-25 | 2023-04-03 | エービー サイエンス | 筋萎縮性側索硬化症患者の下位集団の治療のためのマシチニブの使用 |
| CN107267454A (zh) * | 2016-04-07 | 2017-10-20 | 北京京蒙高科干细胞技术有限公司 | 一种脐血nk细胞的体外扩增方法及其试剂盒与应用 |
| CN110291089B (zh) | 2017-01-17 | 2022-05-27 | 海帕瑞吉尼克斯股份有限公司 | 用于促进肝再生或者减少或预防肝细胞死亡的蛋白激酶抑制剂 |
| EP3576733A4 (en) * | 2017-02-01 | 2020-11-25 | Beyondspring Pharmaceuticals, Inc. | METHOD OF REDUCING NEUTROPENIA |
| WO2020092240A1 (en) * | 2018-10-29 | 2020-05-07 | Northwestern University | Big data-driven personalized management of chronic pain |
| WO2020115108A1 (en) * | 2018-12-06 | 2020-06-11 | Sørlandet Sykehus Hf | Egfr inhibitors and their use in the treatment of neuroathic pain |
| WO2020115261A1 (en) * | 2018-12-07 | 2020-06-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating melanoma |
| CN111759857A (zh) * | 2020-06-30 | 2020-10-13 | 宁波市微循环与莨菪类药研究所 | Gabrd甲基化靶点在制备抗海洛因复吸药物中的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100491374C (zh) | 2002-08-02 | 2009-05-27 | Ab科学公司 | 2-(3-氨基芳基)氨基-4-芳基-噻唑及其作为c-kit抑制剂的应用 |
| US8450302B2 (en) * | 2002-08-02 | 2013-05-28 | Ab Science | 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors |
| US20090298061A1 (en) | 2005-07-29 | 2009-12-03 | Siemens Healthcare Diagnostics Inc. | Diagnostic Methods for the Prediction of Therapeutic Success, Recurrence Free and Overall Survival in Cancer Therapy |
| US20100143935A1 (en) * | 2006-12-01 | 2010-06-10 | Apocell, Inc. | c-KIT Phosphorylation in Cancer |
| EP2117531B1 (en) | 2007-01-12 | 2016-11-02 | AB Science | Combination treatment of solid cancers with antimetabolites and tyrosine kinase inhibitors |
| US8153792B2 (en) | 2007-02-13 | 2012-04-10 | Ab Science | Process for the synthesis of 2-aminothiazole compounds as kinase inhibitors |
| WO2011056963A1 (en) | 2009-11-04 | 2011-05-12 | The University Of North Carolina At Chapel Hill | Methods and compositions for predicting survival in subjects with cancer |
| TW201130830A (en) * | 2010-02-01 | 2011-09-16 | Ab Science | Combined treatment of pancreatic cancer with gemcitabine and masitinib |
| WO2012170640A1 (en) * | 2011-06-07 | 2012-12-13 | The Trustees Of Columbia University In The City Of New York | Methods and compositions for trail-drug combination therapy |
-
2013
- 2013-10-04 SI SI201330891T patent/SI2903616T1/en unknown
- 2013-10-04 MX MX2015004264A patent/MX369999B/es active IP Right Grant
- 2013-10-04 US US14/433,198 patent/US10238649B2/en active Active
- 2013-10-04 SG SG11201502626PA patent/SG11201502626PA/en unknown
- 2013-10-04 EA EA201500373A patent/EA037368B1/ru unknown
- 2013-10-04 CN CN201380063241.4A patent/CN104968347A/zh active Pending
- 2013-10-04 AR ARP130103596A patent/AR092899A1/es unknown
- 2013-10-04 WO PCT/EP2013/070741 patent/WO2014053650A1/en active Application Filing
- 2013-10-04 EP EP13773731.8A patent/EP2903616B8/en active Active
- 2013-10-04 ES ES13773731.8T patent/ES2656640T3/es active Active
- 2013-10-04 AU AU2013326463A patent/AU2013326463B2/en not_active Ceased
- 2013-10-04 BR BR112015007144A patent/BR112015007144A2/pt not_active Application Discontinuation
- 2013-10-04 KR KR1020157011764A patent/KR102149483B1/ko active IP Right Grant
- 2013-10-04 CA CA2886979A patent/CA2886979C/en active Active
- 2013-10-04 JP JP2015535036A patent/JP6234466B2/ja active Active
- 2013-10-04 DK DK13773731.8T patent/DK2903616T3/da active
- 2013-10-04 TW TW102136110A patent/TWI609686B/zh active
- 2013-10-04 NZ NZ706420A patent/NZ706420A/en unknown
-
2015
- 2015-04-01 IL IL238107A patent/IL238107B/en active IP Right Grant
- 2015-04-08 ZA ZA2015/03054A patent/ZA201503054B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2656640T3 (es) | 2018-02-27 |
| SI2903616T1 (en) | 2018-02-28 |
| SG11201502626PA (en) | 2015-05-28 |
| EP2903616B8 (en) | 2018-02-07 |
| JP6234466B2 (ja) | 2017-11-22 |
| TW201414475A (zh) | 2014-04-16 |
| KR102149483B1 (ko) | 2020-08-28 |
| ZA201503054B (en) | 2016-11-30 |
| AU2013326463A1 (en) | 2015-04-16 |
| DK2903616T3 (da) | 2018-01-29 |
| US20150272945A1 (en) | 2015-10-01 |
| JP2015532296A (ja) | 2015-11-09 |
| AU2013326463B2 (en) | 2018-01-18 |
| CA2886979C (en) | 2021-01-05 |
| EP2903616A1 (en) | 2015-08-12 |
| IL238107B (en) | 2018-03-29 |
| BR112015007144A2 (pt) | 2017-12-12 |
| KR20150092739A (ko) | 2015-08-13 |
| EA037368B1 (ru) | 2021-03-19 |
| WO2014053650A1 (en) | 2014-04-10 |
| MX369999B (es) | 2019-11-28 |
| MX2015004264A (es) | 2015-10-12 |
| CA2886979A1 (en) | 2014-04-10 |
| NZ706420A (en) | 2018-08-31 |
| EP2903616B1 (en) | 2017-12-13 |
| CN104968347A (zh) | 2015-10-07 |
| US10238649B2 (en) | 2019-03-26 |
| AR092899A1 (es) | 2015-05-06 |
| TWI609686B (zh) | 2018-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201500373A1 (ru) | Маситиниб или его соль для лечения рака, фармацевтическая композиция, лекарственное средство и набор | |
| Beatty et al. | The biological underpinnings of therapeutic resistance in pancreatic cancer | |
| Zhang et al. | Long non-coding RNA HOTAIR promotes glioblastoma cell cycle progression in an EZH2 dependent manner | |
| Xu et al. | Cisplatin-induced downregulation of miR-199a-5p increases drug resistance by activating autophagy in HCC cell | |
| MX2022006075A (es) | Antagonistas de union a pd-l1 y usos de los mismos para el tratamiento de cancer. | |
| EA201290138A1 (ru) | Производные пиразола как модуляторы кальциевых каналов, активируемых высвобождением кальция | |
| MX2017014381A (es) | Metodos terapeuticos y diagnosticos para cancer. | |
| EA201290139A1 (ru) | Модуляторы кальциевого канала, активируемого высвобождением кальция, представляющие собой производные пиразола, и способы лечения немелкоклеточного рака легких | |
| JP2011521618A5 (ru) | ||
| TR201807411T4 (tr) | DNA-PK inhibitörleri. | |
| EA201591069A1 (ru) | Лечение злокачественной опухоли гетероциклическими ингибиторами глутаминазы | |
| HRP20191145T1 (hr) | Postupak predviđanja ishoda liječenja s afliberceptom kod pacijenta za kojeg se sumnja da ima rak | |
| EA201400197A1 (ru) | Имидазопиразиновые ингибиторы тирозинкиназы syk | |
| EA200971053A1 (ru) | Способы лечения кожных язв | |
| EA201891304A1 (ru) | ИНГИБИТОРЫ MAT2A ДЛЯ ЛЕЧЕНИЯ MTAP-null ЗЛОКАЧЕСТВЕННЫХ ОПУХОЛЕЙ | |
| Wennemers et al. | Regulation of TRIB3 mRNA and protein in breast cancer | |
| EA201890891A1 (ru) | Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение | |
| Sun et al. | Decreased expression of miR-15b in human gliomas is associated with poor prognosis | |
| EA201791535A1 (ru) | Новое соединение 4'-тионуклеозида, а также способ его получения, его фармацевтическая композиция и применение | |
| EA202192122A1 (ru) | Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения | |
| Li et al. | IC-4, a new irreversible EGFR inhibitor, exhibits prominent anti-tumor and anti-angiogenesis activities | |
| EA201401353A1 (ru) | Биомаркеры для определения эффективной ответной реакции на лечение пациентов с гепатоцеллюлярной карциномой (гцк) | |
| Gao et al. | LncRNA PCAT1 activates SOX2 and suppresses radioimmune responses via regulating cGAS/STING signalling in non‐small cell lung cancer | |
| Lv et al. | Neuropeptide Y1 receptor inhibits cell growth through inactivating mitogen-activated protein kinase signal pathway in human hepatocellular carcinoma | |
| RU2016117729A (ru) | Терапия рака путем таргетинга покоящихся раковых клеток |